Stroke Prevention in Symptomatic Large Artery Intracranial Atherosclerosis
Key Points
Key Points
- Over the last 2 decades, evidence has accumulated informing the treatment of symptomatic intracranial atherosclerotic arterial stenosis (s-ICAS) with 2 general approaches emerging:
- aggressive medical management with dual antiplatelet therapy plus intensive control of vascular risk factors, and
- medical therapy plus endovascular procedures.
- Given the high risk of recurrent stroke reported in many studies, clinical trials also focused on identifying and quantifying modifiable and non-modifiable risk factors that may place patients at a particularly high risk of recurrent stroke.
- Knowledge of predictors of recurrent stroke is crucial for risk stratification, effect modification, and identifying therapeutic targets in future clinical trials.
Diagnosis
Diagno...
Clinicians should utilize diagnostic...
Treatment
...reatment...
...linicians should recommend aspirin 325 mg/d o...
...should recommend adding clopidogrel 75 mg/d...
...ns may recommend adding cilostazol 200 mg/d to as...
...ans should recommend high-intensity statin t...
...inicians should recommend a long-t...
...ians should recommend at least moder...
...icians must recommend treatment of o...
...s could not achieve consensus on a...
...ns should NOT recommend percutaneous tran...
...linicians should NOT recommend PTAS fo...
...ns should NOT routinely recommend angioplas...
...cians should counsel patients about th...
...nicians should NOT recommend direct...
...linicians must NOT routinely recommend...
...current Stroke or Death in Patients W...
...k Factor-Control During Follow-upHaving trouble...
...difiable Risk Factors at BaselineHaving t...
...-Modifiable Risk Factors at Baselin...